EOC Pharma Group (Shanghai, China) recently raised $32 million in a series B round led by new investor Taikang. Fellow new investor H&Q Asia Pacific also participated, as did existing investor Sequoia China.
EOC Pharma is a spin-off of the oncology division of Eddingpharm Inc. (Hong Kong, China), in-licenses candidates to develop and commercialize in China.
Xiaoming Zou, Founder and CEO, BioCentury said, “The funds should last about 18 months, and will be used in part to in-license additional late-stage oncology assets. The company has raised about $47 million to date.”
Next year, EOC Pharma plans to start Phase III trials in China of entinostat (EOC103) to treat breast cancer and telatinib (EOC315) to treat gastric cancer. Entinostat is an oral histone deacetylase (HDAC) inhibitor, and telatinib is a small molecule VEGF receptor inhibitor.
EOC Pharma has rights to entinostat in China and certain other Asian countries from Syndax Pharmaceuticals Inc. and worldwide rights to telatinib from ACT Biotech Inc. (San Francisco, Calif.).
